Address: Pieńków 149
05-152 Czosnów k/W-wy
Tel: +48 22 751 85 17
Web: http://www.adamed.com.pl/pl/
Our priority is production of ethical drugs. We are leaders on the market of new generation drugs in many therapeutic groups such as cardiology, psychiatry, pulmonology, gynecology and treatment of urinal tract infections.
We invest in research that is set to find effective and innovative original drugs which can be used for the most common diseases of our time, diabetes, venous thromboembolism (VTE), tumors
In the care of patients, we develop new generic drugs, which can guarantee high quality and safety of therapy.
Cardiology:
Amlozek (amlodipinum)
Areplex (clopidogrelum)
Axtil (ramiprilum)
Nebilenin (nebivololum)
Xartan (losartanum kalicum)
Psychiatry:
Selofen (zaleplonum)
Zolafren (olanzapinum)
Gynecology & Urogynecology:
Colpexin (intravaginal device)
Furaginum (furaginum)
Luteina (progesteronum)
Pulmonology:
Milukante (montelukastum)
Zafiron (formeteroli fumaras)
Gastroenterology:
Anesteloc (pantoprazolum)
Ophthalmology:
Rozacom (dorzolamidum, timololum)
Rozalin (dorzolamidum)
Ingrid Šmerdová, General Manager of Adamed in the Czech Republic and Slovakia, shares her thoughts about the role their future product pipeline will have in continuing to build the company’s…
Taras Velgosh, Adamed’s country manager in Ukraine, provides insights into the great results accomplished by the Ukrainian affiliate of this leading Polish pharmaceutical company despite the deep crisis that has…
“In this very competitive environment, patents give companies an edge; this is why we must maintain innovative breakthroughs in our industry. This will then allow us to compete more efficiently…
Adamed was founded in 1986 by your father, Mr. Marian Adamkiewicz. The company is today still fully-owned by your family, which is remarkable in such an industry, where family-run businesses…
Zszisław Sabiłło, president of the Polish Association of the Pharmaceutical Industry Employers (PZPPF), discusses the significance of the Polish generics market in terms of volume and sales market share, and…
Poland’s entrance into the EU has been a catalyst for growth that has allowed the country to flourish, shown by the nation’s ranking as the eighth largest economy in Europe according…
“Cost containment measures are not just a Polish story, but a European reality,” says Marcin Hanczaruk, general manager at Amgen. “The Reimbursement Act is a real revolution, but it has…
The general director of Actavis Poland talks about competing in an intense generics market, and the company’s potential in Poland given the country’s 2012 Reimbursement Act. The year 2012 was…
AstraZeneca’s General Manager in Poland discuses AstraZeneca’s strategic realignment to become a highly specialized biotech company after 20 years of presence in Poland. He stresses the importance of the affiliate’s…
Novascon Pharmaceuticals is the second fastest growing company in the OTC/dietary supplement market in Poland. Its founder shares the reasons behind this success, including his strategy to sell their main…
Omega Pharma is a pharmacist champion and one of the fastest growing OTC companies in Poland. Its General Manager in Poland discusses the shift taking place with Pharmacies now becoming…
Schulke Poland’s General Manager wants the affiliate: “to be recognized as a high quality “one stop shop” for hygiene and disinfection. He also comments: “Poland is quite advanced in terms…
The department of innovation and industry under the Ministry of Economy has been preparing a new project called: “Pharmaceutical Industry Mapping.” Its leader hopes: “that the outcome of this exercise…
Bristol-Myers Squibb’s General Manager in Poland stresses the urgent need to allow more innovative drugs to fight against deadly diseases, especially in the field of immune-oncology which he says will:…
Unipharm Poland’s country manager explains what is needed to become a successful OTC and dietary supplement company in Poland, saying that it is “key to master the marketing mix but…
Budget limitations in the Polish vaccine field are a handicap to improving patients’ lives as Sanofi Pasteur General Manager comments: “the National Health Fund’s budget for reimbursement is around EUR…
See our Cookie Privacy Policy Here
